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Background: Cutaneous metastases from internal malignancies are uncommon. Moreover, endometrial carcinoma
rarely metastasizes to the skin, with a reported prevalence of 0.8%. Here, we report the case of a 62-year-old woman
who developed cutaneous metastases from an endometrial carcinoma.
Case presentation: When admitted to our department, the patient underwent a biopsy that showed the presence
of cutaneous metastasis in relation to her initial endometrial cancer, diagnosed 3 years earlier. Thereafter, she was
treated with a bilateral uterine artery embolization and chemotherapy. The patient had complications and survived
5 months after the diagnosis of the cutaneous metastasis. She died from sepsis.
Conclusion: Cutaneous metastases of the endometrial carcinoma are usually incurable and suggest an unfortunate
prognosis where palliation is the mainstay of patient management.
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Cutaneous metastases may occur as the initial manifest-
ation of internal malignancy or late in the course of the
disease. The incidence of cutaneous metastases in internal
malignancies has been reported between 0.7% and 10%
[1]. Incidence of various tumors metastasizing to the skin
correlates with the sex-wise frequency of occurrence of
various primary malignancies. As such, lung cancer (1.7 to
3.1%) and breast cancer (23.9%) are the commonest epithe-
lial malignancies metastasizing to the skin in men and
women respectively [2-4]. Furthermore, although endomet-
rial carcinoma is the most common gynecological cancer, it
rarely metastasizes to the skin, with a reported prevalence
of 0.8% [5].
In this paper, we report the case of a 62-year-old woman
with cutaneous metastasis of the endometrial cancer and
describe the clinical and pathological features. We also
discuss the clinical and histopathological criteria for the
differential diagnosis of cutaneous paraneoplastic lesions
and cutaneous metastases. Moreover, we review the lite-
rature to determine and to evaluate both the prognostic
significance and the frequency of this disease.* Correspondence: david.atallah@gmail.com
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A 62-year-old female, Gravida 2, Para 2, was referred to
our department for itching with identifiable pelvic cutane-
ous lesions. She was menopausal at age 51 years. Clinical
examination revealed the presence of cutaneous papulo-
bullous lesions located at the site of the laparotomy inci-
sion extending down to the vulva and up to the umbilicus
(Figure 1). No pelvic mass was palpated on physical exam-
ination. A thoraco-abdomino-pelvic computed tomography
scan was performed and showed no abnormality.
The patient’s previous gynecological history revealed
that she was diagnosed 3 years earlier with endometrial
carcinoma. The histological type of the endometrial adeno-
carcinoma was endometrioid and defined as Féderation
Internationale de Gynécologie et d’Obstétrique stage 1B,
grade 2. A total hysterectomy, bilateral salpingo-oophorec-
tomy, and pelvic lymph node dissection were performed.
Pelvic lymph nodes were negative (seven nodes). The pa-
tient did not undergo any para-aortic lymphadenectomy.
External pelvic radiotherapy was prescribed, leading to a
complete clinical response. During the last 3 years, the
patient had regular check-ups with her oncologist outside
our institution.
When admitted to our department, the patient under-
went a biopsy that showed the presence of cutaneous
metastasis in relation to her initial cancer (Figure 2).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Cutaneous metastasis of the endometrial carcinoma.
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because of important vaginal bleeding, and four cycles
of salvage chemotherapy with etoposide (VP-16) and
cisplatin [6-8].
Three months later, the patient was transfused with 3
units of packed red blood cells because of recurrent
massive vaginal bleeding. She then underwent pelvic
magnetic resonance imaging, which revealed the presence
of a pelvic tumor mass of 15 cm× 8 cm× 4 cm invading
the bladder and rectum. However, pelvic computed tom-
ography angiography identified no signs of active arterial
bleeding. The last months of the patient were marked by
episodes of urinary tract and scar incision infections
(extended-spectrum beta-lactamase Escherichia coli and
Pseudomonas aeruginosa) treated with antibiotics. The
patient died 2 months later from sepsis.Figure 2 Histopathological findings of the skin nodule.
Medium-power photomicrograph (original magnification, ×200;
hematoxylin and eosin stain) of the skin nodule, showing a moderately
differentiated endometrioid adenocarcinoma.Conclusions
Distinguishing between cutaneous paraneoplastic lesions
and those due to invasion of the skin through hematoge-
neous spread, lymphatic spread or by direct extension
from a primary tumor is essential. Paraneoplastic derma-
toses follow the evolution of the underlying cancer and
are due to the production by the tumor of hormones,
cytokines and growth factors [9].
Histopathologically, the type of endometrial carcinoma
that disseminated to the skin was endometrioid adeno-
carcinoma in our case – as the majority of studies that
analyze skin metastases from endometrial cancer also
report [10]. A mixed Müllerian tumor has also been
reported. In these lesions, neoplastic cells appear to be
arranged in a gland-like pattern within the dermis with
different grades of atypia. Metastatic skin disease from
uterine papillary serous carcinoma, an aggressive variant
of endometrial carcinoma mimicking serous papillary
ovarian carcinoma, has been documented [10]. Clinic-
ally, cutaneous metastasis can take any form of lesions
including nodules, papules, ulcers, plaques and tumors,
with usually four histopathological forms involving the
dermis; namely, nodular, infiltrative, diffuse and intravas-
cular [11]. These lesions may be the only manifestation
of an underlying visceral cancer.
The frequency of cutaneous metastasis is correlated to
the frequency of each malignancy, which is why women
with cutaneous metastases most frequently have the
following primary malignancies: breast, ovary, oral cavity,
lung and large intestine [10]. Globally, cutaneous metasta-
ses represent 2% of all cutaneous neoplasms [12].
Although endometrial carcinoma is the most common
gynecological cancer, it only rarely metastasizes to the
skin, with a reported prevalence of 0.8% [5]. A system-
atic English-language literature search on PubMed be-
tween 1966 and 2013 using the terms ‘endometrial
carcinoma’, ‘skin’, ‘cutaneous’, ‘metastasis’ and ‘spread’
identified only 26 cases of cutaneous metastasis in endo-
metrial cancer [13-19]. Most of these reports emphasize
the rarity of this pattern of dissemination. Four points
illustrated in the current case deserve to be discussed.
The strategy for cancer treatment and management in
cutaneous metastases is to determine the tumor origin,
which is achievable with tissue biopsy of the metastatic
nodule. However, this may prove unhelpful in settings
where patients would have visited several hospitals and
had surgeries without histological diagnosis or confirm-
ation of excised lesions [14]. Contrarily, in our case, biopsy
enabled us to confirm the presence of cutaneous metas-
tasis in relation to the initial endometrial cancer of the
patient.
Secondly, in the reported cases, metastasis from endo-
metrial cancer has been most commonly noted at the site
of initial surgery [16], such as in our patient. The initial
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carefully for skin metastasis. More rarely, distant cutane-
ous sites, including scalp, toes and trunk, have been re-
ported [20,21].
Thirdly, cutaneous metastases may vary in number-
from a single nodule to greater than 20 lesions, similarly
to our case.
Finally, cutaneous metastases of the endometrial car-
cinoma are associated with poor prognosis and a mean life
expectancy reported as approximately 4 to 12 months
after the diagnosis of cutaneous metastasis [22,23]. The
factor influencing survival is the time elapsed between
diagnosis and the appearance of the skin recurrences [24].
Furthermore, to date there are no treatments with proven
efficacy because of the rarity of this specific site of metas-
tasis. The treatment for most patients is palliative, and
although chemotherapy and radiotherapy are often used
in these patients, they are ineffective in many cases [25].
In our case, the patient underwent embolization and
etoposide and cisplatin chemotherapy. Etoposide and
cisplatin regimen was prescribed given that these two
agents are more efficacious than the carboplatin and pacli-
taxel regimen in the treatment of advanced endometrial
cancer, as reported by Olawaiye and colleagues in 2012
[6]. Kim and colleagues [7] and Pierga and colleagues [8]
also demonstrated that the combination of etoposide and
cisplatin is an effective regimen with an acceptable toxicity
in patients with recurrent or metastatic endometrial car-
cinoma. Moreover, we considered that the patient had a
second-line treatment for metastatic endometrial car-
cinoma, although the standard of care for women
who present with locally advanced or who experience
relapse with metastatic disease is to proceed with an
anthracycline, taxane and platinum combination [26].
However, the disease evolution was rapidly fatal and the
patient died 5 months after her admission to our depart-
ment due to sepsis.
In conclusion, both our case and the other cases
reported in the literature demonstrate that the appear-
ance of a cutaneous lesion at the site of initial surgery a
few years or months after the diagnosis of endometrial
carcinoma could represent widespread dissemination of
the primary tumor. These cutaneous metastases herald a
poor prognosis and fatal evolution.Consent
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